Novo Nordisk’s Ultra Fast-Acting Insulin On Course To Indian Debut
Novo Nordisk is gearing towards the potential launch of its ultra fast-acting insulin aspart, Fiasp, in India. Pricing and how the product will be positioned alongside NovoRapid (conventional insulin aspart) are expected to be closely watched by competition.
You may also be interested in...
Novo Nordisk’s new India managing director takes charge amid heightened competition in the diabetes space. The Danish firm stays committed to bringing new products to this market at a faster clip and all eyes will be on the launch trajectory of therapies like semaglutide.
Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.
Original new drugs and biologics approved by US FDA.